vs

Side-by-side financial comparison of Ecovyst Inc. (ECVT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $199.4M, roughly 1.1× Ecovyst Inc.). On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 34.0%). Organogenesis Holdings Inc. produced more free cash flow last quarter ($34.8M vs $22.9M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 18.7%).

Ecovyst Inc. is a global sustainable specialty materials provider that develops and manufactures high-performance catalysts and functional additives. Its offerings serve key segments including industrial manufacturing, consumer goods, and environmental protection, helping clients improve operational efficiency and lower carbon emissions across North America, Europe, and Asia-Pacific markets.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ECVT vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.1× larger
ORGO
$225.6M
$199.4M
ECVT
Growing faster (revenue YoY)
ORGO
ORGO
+44.2% gap
ORGO
78.1%
34.0%
ECVT
More free cash flow
ORGO
ORGO
$11.8M more FCF
ORGO
$34.8M
$22.9M
ECVT
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
18.7%
ECVT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ECVT
ECVT
ORGO
ORGO
Revenue
$199.4M
$225.6M
Net Profit
$43.7M
Gross Margin
23.4%
Operating Margin
10.9%
28.1%
Net Margin
19.4%
Revenue YoY
34.0%
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$0.06
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ECVT
ECVT
ORGO
ORGO
Q4 25
$199.4M
$225.6M
Q3 25
$204.9M
$150.9M
Q2 25
$176.1M
$101.0M
Q1 25
$143.1M
$86.7M
Q4 24
$148.9M
$126.7M
Q3 24
$153.9M
$115.2M
Q2 24
$154.0M
$130.2M
Q1 24
$141.6M
$110.0M
Net Profit
ECVT
ECVT
ORGO
ORGO
Q4 25
$43.7M
Q3 25
$-79.3M
$21.6M
Q2 25
$6.0M
$-9.4M
Q1 25
$-3.6M
$-18.8M
Q4 24
$7.7M
Q3 24
$14.3M
$12.3M
Q2 24
$8.3M
$-17.0M
Q1 24
$1.2M
$-2.1M
Gross Margin
ECVT
ECVT
ORGO
ORGO
Q4 25
23.4%
Q3 25
25.4%
Q2 25
22.8%
Q1 25
13.3%
72.6%
Q4 24
28.9%
75.5%
Q3 24
29.3%
76.7%
Q2 24
27.3%
77.6%
Q1 24
23.5%
73.9%
Operating Margin
ECVT
ECVT
ORGO
ORGO
Q4 25
10.9%
28.1%
Q3 25
13.8%
13.7%
Q2 25
9.0%
-12.5%
Q1 25
-0.7%
-30.9%
Q4 24
15.1%
8.1%
Q3 24
17.9%
5.4%
Q2 24
14.1%
-10.7%
Q1 24
9.5%
-3.5%
Net Margin
ECVT
ECVT
ORGO
ORGO
Q4 25
19.4%
Q3 25
-38.7%
14.3%
Q2 25
3.4%
-9.3%
Q1 25
-2.5%
-21.7%
Q4 24
6.1%
Q3 24
9.3%
10.7%
Q2 24
5.4%
-13.1%
Q1 24
0.9%
-1.9%
EPS (diluted)
ECVT
ECVT
ORGO
ORGO
Q4 25
$0.06
$0.31
Q3 25
$-0.69
$0.11
Q2 25
$0.05
$-0.10
Q1 25
$-0.03
$-0.17
Q4 24
$-0.26
$0.05
Q3 24
$0.12
$0.09
Q2 24
$0.07
$-0.13
Q1 24
$0.01
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ECVT
ECVT
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$197.2M
$93.7M
Total DebtLower is stronger
$392.6M
Stockholders' EquityBook value
$603.4M
$300.1M
Total Assets
$1.3B
$598.7M
Debt / EquityLower = less leverage
0.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ECVT
ECVT
ORGO
ORGO
Q4 25
$197.2M
$93.7M
Q3 25
$82.0M
$63.7M
Q2 25
$69.6M
$73.1M
Q1 25
$127.5M
$110.0M
Q4 24
$131.4M
$135.6M
Q3 24
$123.5M
$94.3M
Q2 24
$83.3M
$89.9M
Q1 24
$103.1M
$88.6M
Total Debt
ECVT
ECVT
ORGO
ORGO
Q4 25
$392.6M
Q3 25
$854.8M
Q2 25
$856.6M
Q1 25
$859.0M
Q4 24
$860.8M
Q3 24
$862.7M
$62.3M
Q2 24
$862.4M
$63.8M
Q1 24
$866.2M
$65.2M
Stockholders' Equity
ECVT
ECVT
ORGO
ORGO
Q4 25
$603.4M
$300.1M
Q3 25
$607.9M
$255.1M
Q2 25
$692.4M
$233.2M
Q1 25
$698.7M
$242.9M
Q4 24
$700.5M
$262.9M
Q3 24
$729.4M
$278.5M
Q2 24
$717.3M
$263.5M
Q1 24
$711.4M
$278.0M
Total Assets
ECVT
ECVT
ORGO
ORGO
Q4 25
$1.3B
$598.7M
Q3 25
$1.7B
$509.8M
Q2 25
$1.8B
$461.1M
Q1 25
$1.8B
$467.4M
Q4 24
$1.8B
$497.9M
Q3 24
$1.8B
$446.3M
Q2 24
$1.8B
$443.2M
Q1 24
$1.8B
$458.5M
Debt / Equity
ECVT
ECVT
ORGO
ORGO
Q4 25
0.65×
Q3 25
1.41×
Q2 25
1.24×
Q1 25
1.23×
Q4 24
1.23×
Q3 24
1.18×
0.22×
Q2 24
1.20×
0.24×
Q1 24
1.22×
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ECVT
ECVT
ORGO
ORGO
Operating Cash FlowLast quarter
$41.8M
$39.4M
Free Cash FlowOCF − Capex
$22.9M
$34.8M
FCF MarginFCF / Revenue
11.5%
15.4%
Capex IntensityCapex / Revenue
9.4%
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$69.9M
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ECVT
ECVT
ORGO
ORGO
Q4 25
$41.8M
$39.4M
Q3 25
$55.3M
$3.1M
Q2 25
$33.0M
$-32.9M
Q1 25
$10.3M
$-19.9M
Q4 24
$43.5M
$10.9M
Q3 24
$59.9M
$8.7M
Q2 24
$10.0M
$4.7M
Q1 24
$36.5M
$-10.2M
Free Cash Flow
ECVT
ECVT
ORGO
ORGO
Q4 25
$22.9M
$34.8M
Q3 25
$53.2M
$844.0K
Q2 25
$7.8M
$-36.5M
Q1 25
$-14.0M
$-23.6M
Q4 24
$30.9M
$7.6M
Q3 24
$53.6M
$6.1M
Q2 24
$-9.3M
$2.9M
Q1 24
$19.1M
$-12.4M
FCF Margin
ECVT
ECVT
ORGO
ORGO
Q4 25
11.5%
15.4%
Q3 25
26.0%
0.6%
Q2 25
4.4%
-36.1%
Q1 25
-9.8%
-27.2%
Q4 24
20.7%
6.0%
Q3 24
34.9%
5.3%
Q2 24
-6.1%
2.2%
Q1 24
13.5%
-11.3%
Capex Intensity
ECVT
ECVT
ORGO
ORGO
Q4 25
9.4%
2.1%
Q3 25
1.0%
1.5%
Q2 25
14.4%
3.6%
Q1 25
16.9%
4.2%
Q4 24
8.5%
2.7%
Q3 24
4.1%
2.2%
Q2 24
12.5%
1.4%
Q1 24
12.3%
2.0%
Cash Conversion
ECVT
ECVT
ORGO
ORGO
Q4 25
0.90×
Q3 25
0.14×
Q2 25
5.52×
Q1 25
Q4 24
1.43×
Q3 24
4.21×
0.71×
Q2 24
1.20×
Q1 24
29.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ECVT
ECVT

Industrial Mining Automotive$101.3M51%
Regeneration And Treatment Services$90.0M45%
Other$8.1M4%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons